Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis.
The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis. In addition to glomerulonephritis and a butterfly rash, previously negative tests for antinuclear, anti-dsDNA and anti-Sm antibodies became positive. We assume that rIFN-gamma induced the de novo development of SLE in our patient.
Graninger
W B
WB
2nd Department of Internal Medicine, University of Vienna, Austria.
Hassfeld
W
W
Pesau
B B
BB
Machold
K P
KP
Zielinski
C C
CC
Smolen
J S
JS
D000328:Adult; D000906:Antibodies / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001324:Autoantigens / Q000032:analysis; D005260:Female; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D015151:Immunoblotting; D007371:Interferon-gamma / Q000009:adverse effects* / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications / Q000276:immunology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D017411:Ribonucleoproteins, Small Nuclear; D013997:Time Factors; D055517:snRNP Core Proteins
D000906:Antibodies; D000974:Antibodies, Antinuclear; D001324:Autoantigens; D011994:Recombinant Proteins; D017411:Ribonucleoproteins, Small Nuclear; D055517:snRNP Core Proteins; D007371:Interferon-gamma